An injection molded medical device housing is not simply a plastic cover. It may locate a display or PCB, retain a battery or connector, protect a fluid path, support a seal, provide a cleanable user surface, or control how a device is assembled and handled. The appropriate resin, tool concept, inspection plan and supplier evidence therefore depend on the housing's intended use, direct or indirect body-contact assumptions, mating interfaces, service environment, destination market and customer-controlled specifications. A housing described as "medical" is not automatically suitable for every device or market.
For an overseas OEM, the practical decision is to convert those product needs into an awardable manufacturing baseline. That means specifying what the molder must make and control, what evidence the molder must supply, and what the device owner must retain as a product, regulatory and release decision. ISO 13485 provides a quality-management framework relevant to medical-device organizations and suppliers, while the FDA's QMSR applies to finished-device manufacturers in its stated scope and incorporates ISO 13485:2016 by reference [1] [2]. Neither source turns a resin datasheet, supplier audit or molded sample into automatic market authorization. This guide focuses on housing-specific procurement and quality questions rather than making an approval claim for any part, tool or supplier.
Requirement: the device owner must define the controlled product requirements and release authority. Recommendation: require the molder to show how its proposed material route, tooling, molding controls and inspection records support those requirements before production release.
01
1. Classify the housing before requesting a quote or supplier evidence
Start with a short housing requirement brief, not a generic request for a "medical-grade enclosure." State the device function, intended users, target countries, product classification assumptions where known, contact pathway, expected life, reuse and cleaning method, likely sterilization or disinfectant exposure, temperature and humidity range, drop or load condition, ingress or sealing target if applicable, cosmetic zones, and all interfaces. Identify whether the housing merely surrounds a device, contacts intact skin, is near a fluid path, becomes part of a patient-contacting assembly, or can transfer materials to another contacting component. The device owner, not the molder, should decide the applicable regulatory pathway and acceptance criteria with qualified regulatory and quality input.
Make the controlled baseline visible in the RFQ: drawing and CAD revision, critical dimensions and datums, mating components, approved or candidate resin grades, colour and texture reference, metal inserts, labels, coatings, gasket details, planned annual volumes, packaging and delivery terms. Requirements are the attributes that must be met. Recommendations are decisions a supplier may propose, such as a different gate location, wall adjustment or cavity approach; they require review against the controlled baseline. This distinction prevents an apparently helpful DFM suggestion from silently changing a sealing face, latch force, visible surface or electronics clearance.
For any body-contacting or indirectly contacting configuration, do not decide suitability from a polymer family name alone. FDA guidance on ISO 10993-1 addresses devices with direct or indirect human-body contact and describes a risk-based approach to determining whether biocompatibility testing is needed [3]. The finished configuration matters: resin, pigment or additive package, processing history, surface treatment, contamination controls, assembly materials and exposure can all affect the evidence needed. Ask the responsible device team to document the intended-use assumptions that the supplier must preserve, rather than asking the supplier to make a blanket biocompatibility or regulatory claim.
02
2. Select resin and housing architecture as one engineering decision
Compare candidate materials against the housing function and verified data for the exact grade, not a broad label such as PC, PC/ABS, ABS, PBT, nylon or polypropylene. A transparent or impact-resistant housing may point the review toward one set of properties, while repeated cleaning chemicals, heat, electrical insulation, stiffness, snap-fit fatigue, dimensional stability, color retention or flame-related requirements may change the direction. Filled versus unfilled grades, colour concentrates, recycled-content allowances and supplier-approved regrind rules can alter flow, shrinkage, surface appearance and mechanical behavior. Obtain resin manufacturer documentation and confirm the permitted material route, including who may substitute grades, colors or additives. Product-specific testing and regulatory review remain necessary where the application demands them.
The molding geometry controls whether a good material choice becomes a stable production part. Review nominal wall transitions, ribs and bosses, screw or insert loads, snap locations, parting lines, gate position, weld lines, ejection areas, draft, texture, sealing lands, display windows, connector cutouts and circuit-board clearance. A thick-to-thin transition can affect packing and sink risk; an insert can concentrate stress; a cosmetic front face may restrict gate and ejector choices. There is no universal wall thickness, tolerance or cycle-time promise for medical housings. Results depend on the resin, geometry, tool cooling and venting, machine capability, process window, cavity count, post-mold conditioning, measurement method, volume and customer specifications.
Treat secondary operations as part of the housing design, not an afterthought. Ultrasonic welding, adhesive bonding, overmolding, pad printing, laser marking, painting, EMI shielding, gasket installation, assembly and cleaning can affect fit, appearance, extractables, chemical resistance or traceability. Ask whether the quoted route includes each operation, who controls it, what inspection follows it, and whether subcontracting is proposed. If a supplier suggests a material or process change to reduce cost or lead time, require a documented impact assessment and an approval route before it is used on released output.
03
3. Qualify the proposed manufacturing route with evidence, not supplier labels
A capable molder for a general plastic enclosure may still be a poor fit for a controlled medical-device housing programme. Request evidence that is specific to the proposed route and part risk. This can include a documented quotation scope, DFM review, preliminary tool concept, resin identity and handling plan, process flow, inspection strategy, calibration-status evidence for relevant measurement equipment, sample traceability approach, nonconformance handling, change-notification procedure and a list of planned subcontracted operations. A certificate, marketing statement or clean production photograph should not substitute for this route-level review. If a certificate is contractually required, verify its issuing body, scope, site, validity and relevance independently.
Use supplier evidence to answer a decision question at a named approval gate. For example, the buyer may need confidence that a resin lot can be linked to a molded lot, that the tool can protect a sealing interface, or that a measurement report identifies cavity and revision where those distinctions matter. The scope should be proportionate: an internal, non-contacting battery cover and a reusable exterior housing exposed to aggressive cleaning do not necessarily need the same record set. ISO states that ISO 13485 can be used by organizations involved in the design, production, installation and servicing of medical devices and by suppliers and external parties; the buyer should nevertheless define the supplier's actual responsibility and evidence boundary [2].
The table is a practical request matrix rather than a universal regulatory checklist. Add customer- and market-specific evidence only when the device owner determines it is needed. Keep the supplier's response tied to the named part number, revision and production site so that a generic capability presentation does not get mistaken for an approved production route.
| Decision area | Evidence to request | Buyer review question | Suggested approval gate |
|---|---|---|---|
| Material route | Exact resin grade, approved colour/additive route, lot-identification method, drying/handling plan and substitution rule. | Can the proposed material route be traced and controlled against the part specification? | Before purchase order or material release |
| Tool and part design | DFM, preliminary gate/parting/ejection concept, critical-feature and cosmetic-risk comments, and open-assumption list. | Do proposed design-for-manufacture changes preserve functional, sealing, assembly and appearance requirements? | Before steel cut |
| Molding and inspection route | Process flow, cavity identification approach where relevant, measurement-plan proposal, equipment/fixture assumptions and reaction plan for nonconformance. | Can the intended route demonstrate the agreed features under the defined sample conditions? | Before trial-plan approval |
| Release and change control | Sample report, deviation log, material and tool identity, change-notification procedure, subcontractor disclosure and record-retention proposal. | Is the evidence sufficient for this release decision, and are later changes routed to the correct approver? | Before production or shipment release |
04
4. Define tooling, process and inspection approval gates for the actual housing
Do not treat payment for a mold as permission to proceed without technical gates. A practical sequence is: controlled requirement brief; DFM disposition; tool-design review; authorization to build; documented trial plan; sample and measurement review; closure of deviations; production or shipment release. At each gate, record the input revision, decision owner, accepted assumptions, open risks, actions and whether the supplier may proceed. The sequence and depth should be adjusted for programme risk, but a written gate structure helps overseas teams avoid time-zone and language gaps becoming undocumented design changes.
For the trial, define what will represent the intended route: tool and cavity identity, resin lot and color route, machine and drying conditions as relevant, inserts or gaskets, secondary operations, sample quantity, post-mold conditioning, measurement timing, fixtures, test methods and acceptance criteria. A dimensional report should identify the part revision and feature, nominal and tolerance where applicable, actual result, unit, method, sample identity and any cavity or condition information that affects interpretation. For cosmetic housings, agree the viewing condition, approved reference and zone classification before visual samples are judged.
Process validation should not be requested as a slogan. FDA's inspection guide describes validation as objective evidence that a process consistently produces output meeting predetermined specifications and explains that validation is relevant when results cannot be fully verified by subsequent inspection and test [4]. That historical guidance is useful context, not a universal instruction that every molded housing needs the same protocol. The device owner should define the applicable requirement, protocol boundary, acceptance criteria, records, sampling rationale and approval authority. A molder should not self-declare a process or finished device approved solely because a trial passed or process settings were recorded.
05
5. Award and manage the housing supply chain after first release
Normalize quotations before award. Compare the same drawing revision, resin direction, annual volume, tool life assumption, cavity proposal, secondary operations, inspection scope, packaging, delivery term and currency. Separate one-time tooling, fixtures, sampling, validation support and recurring part price. Ask what is included and excluded, which assumptions affect price or timing, and what starts each schedule milestone. Tool build, sampling and production timing depend on design maturity, tool complexity, resin availability, machine loading, corrections, testing, approvals, freight and customer response; require a dated milestone plan rather than a universal lead-time promise.
Put control of buyer-owned or buyer-funded tooling in the agreement: identification, location, access, maintenance, repair authority, spare components, storage, insurance, transfer conditions, design and maintenance records, and notification before a change. Define who can approve a resin-grade switch, colorant change, alternate site, machine change, cavity addition or removal, mold repair affecting the part, subcontractor change, measurement-method change, packaging change or temporary deviation. The response may be review only, a new sample, partial evidence, revalidation or another action depending on the housing and customer requirements; it should never be assumed to be identical for every change.
After launch, use incoming performance and supplier data to keep the approval meaningful. Review lot traceability, complaint or nonconformance trends, containment effectiveness, on-time delivery, recurring measurement issues and overdue change actions against the agreed baseline. Require a written impact assessment before implementation when a supplier proposes a change. Procurement can then protect continuity without overruling engineering and quality: the commercial award remains linked to the part-specific technical requirements, evidence and release authority that justified it.
Practical takeaway
Before you move
to the next review.
- Issue a controlled housing brief covering intended use, contact pathway, markets, service environment, interfaces, cosmetic zones, acceptance criteria and responsible approvers.
- Compare resin candidates and secondary operations against the exact housing function, finished configuration and customer-approved material route; do not rely on a polymer-family label.
- Request route-specific supplier evidence for material traceability, DFM, tooling, molding, inspection, nonconformance and change control before award.
- Approve work in gates: DFM disposition, tool design, build authorization, trial plan, sample review, deviation closure and production or shipment release.
- Contractually define tool control, subcontracting disclosure, change-notification triggers, evidence needed after a change and final buyer release authority.
FAQ
Common questions
What should an injection molded medical device housing supplier provide before award?
Request evidence tied to the quoted part and route: quotation assumptions, DFM and tool concept, exact material direction, process and inspection proposal, traceability approach, change-control procedure, disclosure of subcontracted operations and a milestone plan. The device owner should first define what acceptance decision the evidence must support. A general brochure or certificate does not prove that the supplier can make the released housing to its particular requirements.
Are PC, PC/ABS or PBT automatically suitable for medical device housings?
No. These material families can be candidates, but selection depends on the exact grade, additives and colour route, patient-contact assumptions, cleaning or sterilization exposure, mechanical loads, electrical and thermal needs, geometry, processing conditions and customer specifications. Review resin-maker data and the finished configuration, then obtain the product-specific testing or assessment the device owner determines is required.
Does a housing without direct patient contact need biocompatibility evidence?
Not automatically, but it should not be dismissed by label alone. FDA's ISO 10993-1 guidance concerns devices with direct or indirect human-body contact and supports a risk-based assessment [3]. The device owner should document the contact pathway, materials, finished configuration and applicable market requirements with qualified regulatory and quality input. The molder can provide material and process traceability, but should not make the device-level conclusion on its own.
Does approval of a first molded sample release the supplier for routine production?
No. A first sample may support an early dimensional, cosmetic, assembly or process decision, but it is not automatically evidence for all later production. Record what route, tool, cavity context, material, secondary operations, sample condition and requirements were reviewed. Then state whether the decision permits further trials, conditional production, shipment or no release. Subsequent changes should be assessed against that documented baseline.
References
Source material
- [1] U.S. Food and Drug Administration, Quality Management System Regulation (QMSR)
- [2] International Organization for Standardization, ISO 13485:2016 Medical devices — Quality management systems — Requirements for regulatory purposes
- [3] U.S. Food and Drug Administration, Use of International Standard ISO 10993-1: Biological evaluation of medical devices
- [4] U.S. Food and Drug Administration, Guide to Inspections of Medical Device Manufacturers: Process Validation
This guide is general information for early procurement and engineering discussion. It does not replace product-specific DFM, qualification, validation, regulatory assessment or legal advice.